| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥1.53T | ¥1.46T | +5.0% |
| Cost of Sales | ¥1.42T | ¥1.35T | +5.2% |
| Gross Profit | ¥105.75B | ¥102.31B | +3.4% |
| SG&A Expenses | ¥89.54B | ¥87.31B | +2.6% |
| Operating Income | ¥16.21B | ¥14.99B | +8.1% |
| Non-operating Income | ¥1.86B | ¥1.65B | +12.8% |
| Non-operating Expenses | ¥579M | ¥363M | +59.5% |
| Ordinary Income | ¥17.48B | ¥16.28B | +7.4% |
| Profit Before Tax | ¥17.86B | ¥20.67B | -13.6% |
| Income Tax Expense | ¥6.24B | ¥6.90B | -9.5% |
| Net Income | ¥11.62B | ¥13.77B | -15.6% |
| Net Income Attributable to Owners | ¥11.52B | ¥14.06B | -18.1% |
| Total Comprehensive Income | ¥13.54B | ¥17.77B | -23.8% |
| Depreciation & Amortization | ¥6.99B | ¥7.13B | -1.9% |
| Interest Expense | ¥174M | ¥144M | +20.8% |
| Basic EPS | ¥63.35 | ¥75.26 | -15.8% |
| Dividend Per Share | ¥31.00 | ¥31.00 | +0.0% |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥1.15T | ¥1.09T | +¥53.38B |
| Cash and Deposits | ¥175.45B | ¥177.09B | ¥-1.64B |
| Accounts Receivable | ¥680.95B | ¥645.78B | +¥35.17B |
| Inventories | ¥166.70B | ¥157.29B | +¥9.41B |
| Non-current Assets | ¥352.86B | ¥345.39B | +¥7.47B |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥30.56B | ¥2.94B | +¥27.62B |
| Investing Cash Flow | ¥-15.80B | ¥-8.44B | ¥-7.36B |
| Financing Cash Flow | ¥-6.80B | ¥-7.53B | +¥725M |
| Free Cash Flow | ¥14.76B | - | - |
| Item | Value |
|---|---|
| Net Profit Margin | 0.8% |
| Gross Profit Margin | 6.9% |
| Current Ratio | 121.0% |
| Quick Ratio | 103.4% |
| Debt-to-Equity Ratio | 2.07x |
| Interest Coverage Ratio | 93.14x |
| EBITDA Margin | 1.5% |
| Effective Tax Rate | 35.0% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +5.0% |
| Operating Income YoY Change | +8.1% |
| Ordinary Income YoY Change | +7.4% |
| Net Income Attributable to Owners YoY Change | -18.1% |
| Total Comprehensive Income YoY Change | -23.8% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 191.30M shares |
| Treasury Stock | 9.58M shares |
| Average Shares Outstanding | 181.85M shares |
| Book Value Per Share | ¥2,687.54 |
| EBITDA | ¥23.20B |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥31.00 |
| Year-End Dividend | ¥32.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| DispensingPharmacyAndRelatedBusinesses | ¥18.28B | ¥156M |
| EthicalPharmaceuticalsWholesaling | ¥1.37T | ¥14.75B |
| Manufacturing | ¥25.58B | ¥-98M |
| SelfMedicationProductsWholesaling | ¥135.55B | ¥1.76B |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥3.11T |
| Operating Income Forecast | ¥37.10B |
| Ordinary Income Forecast | ¥39.70B |
| Net Income Attributable to Owners Forecast | ¥36.00B |
| Basic EPS Forecast | ¥198.07 |
| Dividend Per Share Forecast | ¥34.00 |
| Property, Plant & Equipment | ¥195.70B | ¥192.44B | +¥3.26B |
| Intangible Assets | ¥12.00B | ¥11.46B | +¥539M |
| Goodwill | ¥1.20B | ¥1.40B | ¥-202M |
| Investment Securities | ¥115.80B | ¥115.31B | +¥485M |
| Total Assets | ¥1.50T | ¥1.44T | +¥60.85B |
| Current Liabilities | ¥948.76B | ¥894.96B | +¥53.80B |
| Accounts Payable | ¥900.35B | ¥834.92B | +¥65.42B |
| Non-current Liabilities | ¥63.60B | ¥62.67B | +¥922M |
| Long-term Loans | ¥10.00B | ¥10.00B | ¥0 |
| Total Liabilities | ¥1.01T | ¥957.64B | +¥54.72B |
| Total Equity | ¥488.38B | ¥482.25B | +¥6.13B |
| Capital Stock | ¥18.45B | ¥18.45B | ¥0 |
| Capital Surplus | ¥31.75B | ¥31.75B | ¥0 |
| Retained Earnings | ¥403.94B | ¥399.65B | +¥4.29B |
| Treasury Stock | ¥-21.55B | ¥-21.37B | ¥-179M |
| Owners' Equity | ¥487.82B | ¥481.79B | +¥6.03B |
| Working Capital | ¥199.11B | - | - |